Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott M Wasserman

Showing results (61-70 of 97) with videos related to

Pageof 10
Sort By:
Clinical Cardiology|February 17, 2017
Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trialRobert P Giugliano, Francois Mach, Kenton Zavitz, et al.
The New England Journal of Medicine|March 18, 2017
Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseMarc S Sabatine, Robert P Giugliano, Anthony C Keech, et al.
JACC. Heart Failure|December 3, 2014
Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and anginaBarry H Greenberg, Willis Chou, Khalil G Saikali, et al.
Stroke|April 22, 2020
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable AtherosclerosisRobert P Giugliano, Terje R Pedersen, Jeffrey L Saver, et al.
Journal of the American College of Cardiology|June 15, 2019
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER TrialDavid M Charytan, Marc S Sabatine, Terje R Pedersen, et al.
American Journal of Preventive Cardiology|July 30, 2021
C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOVAdam J Nelson, Rishi Puri, Danielle M Brennan, et al.
American Journal of Preventive Cardiology|August 10, 2021
Erratum to "C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights From GLAGOV" [American Journal of Preventive Cardiology 3C (2020) 100091]Adam J Nelson, Rishi Puri, Danielle M Brennan, et al.
American Heart Journal|June 7, 2016
Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)Rishi Puri, Steven E Nissen, Ransi Somaratne, et al.
The New England Journal of Medicine|March 17, 2015
Efficacy and safety of evolocumab in reducing lipids and cardiovascular eventsMarc S Sabatine, Robert P Giugliano, Stephen D Wiviott, et al.
Journal of the American College of Cardiology|February 11, 2014
Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trialsFrederick J Raal, Robert P Giugliano, Marc S Sabatine, et al.
Pageof 10

Showing results (61-70 of 97) with videos related to

Sort By:
Pageof 10
Clinical Cardiology|February 17, 2017
Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trialRobert P Giugliano, Francois Mach, Kenton Zavitz, et al.
The New England Journal of Medicine|March 18, 2017
Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseMarc S Sabatine, Robert P Giugliano, Anthony C Keech, et al.
JACC. Heart Failure|December 3, 2014
Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and anginaBarry H Greenberg, Willis Chou, Khalil G Saikali, et al.
Stroke|April 22, 2020
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable AtherosclerosisRobert P Giugliano, Terje R Pedersen, Jeffrey L Saver, et al.
Journal of the American College of Cardiology|June 15, 2019
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER TrialDavid M Charytan, Marc S Sabatine, Terje R Pedersen, et al.
American Journal of Preventive Cardiology|July 30, 2021
C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOVAdam J Nelson, Rishi Puri, Danielle M Brennan, et al.
American Journal of Preventive Cardiology|August 10, 2021
Erratum to "C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights From GLAGOV" [American Journal of Preventive Cardiology 3C (2020) 100091]Adam J Nelson, Rishi Puri, Danielle M Brennan, et al.
American Heart Journal|June 7, 2016
Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)Rishi Puri, Steven E Nissen, Ransi Somaratne, et al.
The New England Journal of Medicine|March 17, 2015
Efficacy and safety of evolocumab in reducing lipids and cardiovascular eventsMarc S Sabatine, Robert P Giugliano, Stephen D Wiviott, et al.
Journal of the American College of Cardiology|February 11, 2014
Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trialsFrederick J Raal, Robert P Giugliano, Marc S Sabatine, et al.
Pageof 10